Replies to post #188829 on Biotech Values

[dewophile]

thx for posting the latest numbers. NRx is approaching 10% penetration without ESRX and some of the smaller exclusives that have yet to really come on line like NY Medicaid. I'm quite confident now that by Q2 ABBV/ENTA will have 20% market share in the US. Curious ENTA is trading down today